Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer

Abstract

The oncogenic MET exon 14 skipping mutation (METex14del) is described to drive 1.3 %-5.7 % of non-small-cell lung cancer (NSCLC) and multiple studies with cMET inhibitors show promising clinical responses. RNA-based analysis seems most optimal for METex14del detection, however, acquiring sufficient RNA material is often problematic. An alternative is DNA-based analysis, but commercially available DNA-based panels only detect up to 63 % of known METex14del alterations. The goal of this study is to describe an optimized DNA-based diagnostic test for METex14del in NSCLC, including clinical features and follow-up of patients treated with cMET-targeted therapy and consequent resistance mechanisms. Material and methods: Routinely processed diagnostic pathology non-squamous NSCLC specimens were investigated by a custom-made DNA-based targeted amplicon-based next generation sequencing (NGS) panel, which includes 4 amplicons for METex14del detection. Retrospectively, histopathological characteristics and clinical follow up were investigated for advanced non-squamous NSCLC with METex14del. Results: In silico analysis showed that our NGS panel is able to detect 96 % of reported METex14 alterations. METex14del was found in 2 % of patients with non-squamous NSCLC tested for therapeutic purposes. In total, from May 2015-Sep 2018, METex14del was found in 46 patients. Thirty-six of these patients had advanced nonsquamous NSCLC, they were predominantly elderly (76.5 years [53-90]), male (25/36) and (ex)-smokers (23/ 36). Five patients received treatment with crizotinib (Pfizer Oncology), in a named patient based program, disease control was achieved for 4/5 patients (3 partial responses, 1 stable disease) and one patient had a mixed response. Two patients developed a MET D1228N mutation during crizotinib treatment, inducing a resistance mechanism to crizotinib. Conclusions: This study shows that METex14del can be reliably detected by routine DNA NGS analysis. Although a small cohort, patients responded well to targeted treatment, underlining the need for routine testing of METex14del in advanced non-squamous NSCLC to guarantee optimal personalized treatment.

The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder

“…This panel comprised 330 amplicons covering 41 genes, multiple hotspot regions in various cancer‐related genes and 154 single nucleotide polymorphisms in multiple tumor suppressor regions to detect copy number variations (Table 2 and Supplementary Table 3). 5‐7 NGS was performed with the Ion Torrent platform using supplier's materials and protocols (Thermo Fisher Scientific). Median coverage depths were 1994x for UTUC, 1712x for UCB and 1914x for the adjacent normal tissue.…”

Anisometric Cell and Dysplastic Lipomas in a Retinoblastoma Patient

“…Normal tissue from an endometrial sample was included for RB1 genetic analyses. 4 Molecular investigation was performed by Sanger sequencing and targeted next-generation sequencing (NGS) with a custom-made panel V5.1 (information available on request; Ion Torrent, Thermo Fisher Scientific, Waltham, MA), both by laboratory developed tests and targeted sequencing for sarcoma translocations (Archer FusionPlex Sarcoma kit; ArcherDX, Boulder, CO). RB1 loss by NGS with 9 single nucleotide polymorphism (SNP) markers was analyzed by SNPitty.…”

Correlation of clinical, radiologic and pathologic manifestations with prognosis in lung cancer patients

“…Molecular biology of lung cancer appears to be the hallmark and the most signifi cant marker of patient prognosis. For lung cancer treatment, blocking tumor growth by targeting the surrounding angiogenesis, protumorigenic growth factor activation, anti-apoptotic cascades and other cancer-promoting signal transduction events are extremely important and incredibly effective for prolonging patient survival [12][13][14][15][16]…”